- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different": AARP Says High Prescription Drug Prices Will Impact All Americans
In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries. This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA.
In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries.
This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA. Purvis is the director of health services research at the AARP Public Policy Institute, where she leads a team of policy analysts and researchers who work on health care issues that are relevant to the population of Americans aged 50 or older.
We discussed the drug pricing report, the burden that older Americans face from high out-of-pocket costs, and possible policy solutions.
Read more about the AARP report, the White House Council of Economic Advisors report, and AARP’s Stop Rx Greed campaign.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
